CEACAM5 and colorectal carcinoma: A2B530 is a CAR-T cell therapy developed by A2 Biotherapeutics, specifically designed to target CRC expressing CEA and demonstrating human leukocyte antigen (HLA)-A02 loss of heterozygosity.